Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study.
We investigated the potential of cross-over to the serotonin receptor (5HT3) antagonist ondansetron after protection failure with tropisetron. Several cases of complete protection were observed. These limited data suggest that there is an indication for retreatment with a different 5HT3 antagonist after an initial failure to another and also stress the need and relevance for comparative studies between 5HT3 antagonists.
de Boer
M
M
Department of Medical Oncology, Rotterdam Cancer Institute/Dr. Daniel den Hoed Kliniek, The Netherlands.
de Wit
R
R
Stoter
G
G
Verweij
J
J
D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects; D018592:Cross-Over Studies; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control; D017294:Ondansetron / Q000627:therapeutic use*; D010865:Pilot Projects; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D000077526:Tropisetron; D014839:Vomiting / Q000517:prevention & control
D000932:Antiemetics; D007211:Indoles; D012702:Serotonin Antagonists; D017294:Ondansetron; D000077526:Tropisetron; D002945:Cisplatin